LT2170396T - Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui - Google Patents

Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui

Info

Publication number
LT2170396T
LT2170396T LTEP08788620.6T LT08788620T LT2170396T LT 2170396 T LT2170396 T LT 2170396T LT 08788620 T LT08788620 T LT 08788620T LT 2170396 T LT2170396 T LT 2170396T
Authority
LT
Lithuania
Prior art keywords
treatment
muscular dystrophy
drug combinations
duchenne muscular
duchenne
Prior art date
Application number
LTEP08788620.6T
Other languages
English (en)
Inventor
Graham Michael Wynne
Stephen Paul Wren
Peter David Johnson
Paul Damien Price
Olivier De Moor
Gary Nugent
Richard Storer
Richard Joseph Pye
Colin Richard Dorgan
Jonathon Mark Tinsley
Original Assignee
Summit (Oxford) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2170396(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0715088A external-priority patent/GB0715088D0/en
Priority claimed from GB0807216A external-priority patent/GB0807216D0/en
Application filed by Summit (Oxford) Limited filed Critical Summit (Oxford) Limited
Publication of LT2170396T publication Critical patent/LT2170396T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP08788620.6T 2007-08-03 2008-08-01 Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui LT2170396T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0715088A GB0715088D0 (en) 2007-08-03 2007-08-03 Drug combinations for the treatment of duchenne muscular dystrophy
GB0807216A GB0807216D0 (en) 2008-04-21 2008-04-21 Drug combination for the treatment of duchenne muscular dystrophy
PCT/GB2008/050648 WO2009019504A1 (en) 2007-08-03 2008-08-01 Drug combinations for the treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
LT2170396T true LT2170396T (lt) 2017-03-10

Family

ID=40019245

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP08788620.6T LT2170396T (lt) 2007-08-03 2008-08-01 Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui

Country Status (23)

Country Link
US (2) US8501713B2 (lt)
EP (2) EP3251694A1 (lt)
JP (1) JP2010535708A (lt)
CN (1) CN101678107A (lt)
AR (1) AR068332A1 (lt)
AU (1) AU2008285289A1 (lt)
BR (1) BRPI0811317A2 (lt)
CA (1) CA2685540C (lt)
CL (1) CL2008002279A1 (lt)
CY (1) CY1118700T1 (lt)
DK (1) DK2170396T3 (lt)
ES (1) ES2617957T3 (lt)
HR (1) HRP20170313T1 (lt)
HU (1) HUE033195T2 (lt)
LT (1) LT2170396T (lt)
MX (1) MX2009012558A (lt)
PE (1) PE20090510A1 (lt)
PL (1) PL2170396T3 (lt)
PT (1) PT2170396T (lt)
RS (1) RS55735B1 (lt)
SI (1) SI2170396T1 (lt)
TW (1) TW200911237A (lt)
WO (1) WO2009019504A1 (lt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
MX2008016343A (es) * 2006-06-23 2009-01-19 Abbott Lab Derivados ciclopropil amina como moduladores del receptro de histamina h3.
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
UA116871C2 (uk) 2006-12-18 2018-05-25 Акселерон Фарма Інк. СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
PT2170396T (pt) 2007-08-03 2017-03-31 Summit Corp Plc Combinação de fármacos para o tratamento da distrofia muscular de duchenne
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
AU2009296820B2 (en) 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8563746B2 (en) 2008-10-29 2013-10-22 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
WO2010108187A2 (en) * 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
GB0905667D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
JP5540640B2 (ja) 2009-10-07 2014-07-02 住友化学株式会社 複素環化合物及びその有害節足動物防除用途
KR101194995B1 (ko) * 2009-10-14 2012-10-29 주식회사 이큐스앤자루 신규한 2-페닐-벤즈이미다졸 또는 2-페닐-벤즈옥사졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스용 약학적 조성물
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
BR112012019515A2 (pt) 2010-02-03 2018-03-13 The University Of Tokyo indutor de continuação de leitura, e agente terapêutico para doenças genéticas do tipo de mutações anti-senso
WO2011099832A2 (en) * 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
JP5544940B2 (ja) * 2010-03-10 2014-07-09 Ｊｎｃ株式会社 インドール環を有する化合物、液晶組成物、及び液晶表示素子
US20130090371A1 (en) * 2010-04-20 2013-04-11 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CN103037694B (zh) 2010-06-23 2014-08-13 住友化学株式会社 防治有害节肢动物的组合物和杂环化合物
EP2586462A4 (en) * 2010-06-28 2013-12-11 Masatoshi Hagiwara PROPHYLACTIC OR ALTERNATIVE AGENT FOR GENETIC DISEASES
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
WO2012102937A2 (en) * 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
CN102617478B (zh) * 2011-01-31 2015-07-15 华东理工大学 苯并咪唑、噁唑和噻唑衍生物的合成及其应用
CN103748085A (zh) 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
US20140080896A1 (en) * 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
WO2013049407A2 (en) * 2011-09-30 2013-04-04 Kineta, Inc Anti-viral compounds
WO2013120040A1 (en) * 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
CA2864954C (en) 2012-03-06 2020-10-13 Compound Handling B.V. Aminomethylene pyrazolones with therapeutic activity.
EP2636673A1 (en) * 2012-03-06 2013-09-11 Compound Handling B.V. Aminomethylene pyrazolones with therapeutic activity
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
CA2888369A1 (en) 2012-10-17 2014-04-24 F. Hoffmann-La Roche Ag 6-aminoindole derivatives as trp channel antagonists
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
SG11201507135XA (en) 2013-03-15 2015-10-29 Abbott Lab Methods of maintaining and improving muscle function
JP2016516825A (ja) * 2013-04-19 2016-06-09 シーダーズ−サイナイ メディカル センター 筋ジストロフィーの治療のためのホスホジエステラーゼ５ａ阻害物質
WO2014190250A1 (en) * 2013-05-23 2014-11-27 The Johns Hopkins University Activators of soluable guanylate cyclase and their use in treatment of duchenne muscular dystrophy and related disease
ES2838625T3 (es) * 2014-04-14 2021-07-02 Shanghai hengrui pharmaceutical co ltd Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) * 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
WO2017127627A1 (en) * 2016-01-21 2017-07-27 The University Of North Carolina At Chapel Hill Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
CN105712950B (zh) * 2016-01-27 2019-05-21 中国科学院化学研究所 基于苯并噻唑的酰胺类化合物及其制备方法和应用
KR102382188B1 (ko) * 2016-03-17 2022-04-05 주식회사 체크메이트테라퓨틱스 NamPT 억제용 신규 화합물 및 이를 포함하는 조성물
MX2018012018A (es) * 2016-03-30 2019-07-04 Summit Oxford Ltd Composicion para el tratamiento de la distrofía muscular de duchenne.
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
BR112021006843A2 (pt) 2018-10-10 2021-07-13 Albert Einstein College Of Medicine benzoxazol e compostos relacionados úteis como moduladores de autofagia mediada por chaperona
CN109400536A (zh) * 2018-12-21 2019-03-01 东华大学 一种n取代苯并咪唑二胺及其制备方法
KR102658031B1 (ko) * 2018-12-27 2024-04-18 제이투에이치바이오텍 (주) 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
CN109730999B (zh) * 2018-12-28 2021-12-24 中山大学 噻唑苯甲酰胺衍生在制备抗骨质疏松、抗骨关节炎药物中的应用
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
CN109912424B (zh) * 2019-03-01 2020-08-07 浙江大学 硝基苯胺类物质水解成酚的方法
CN114269721B (zh) * 2019-06-12 2024-12-20 Tmem16A有限公司 用于治疗呼吸系统疾病的化合物
EP4077320A4 (en) * 2019-12-16 2024-01-03 The University of British Columbia ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
CN119816500A (zh) 2021-08-20 2025-04-11 拜欧米富士恩公司 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
CN116262744A (zh) * 2021-12-13 2023-06-16 复旦大学 用于α-突触核蛋白聚集体成像的小分子探针
AU2022428183A1 (en) * 2021-12-27 2024-07-11 Astellas Pharma Inc. Substituted quinoline derivative
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
WO2025189127A1 (en) * 2024-03-08 2025-09-12 Automera PTE. LTD Benzofuran derivatives for targeting autophagy

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628695A (lt) 1962-02-21
BE637389A (lt) 1962-09-13
US3993659A (en) 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
CH561242A5 (lt) 1971-08-10 1975-04-30 Ciba Geigy Ag
CH617809GA3 (lt) 1975-10-10 1980-06-30
US4110246A (en) 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3027479A1 (de) 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JPS615071A (ja) 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
JP2615805B2 (ja) 1988-04-15 1997-06-04 ミノルタ株式会社 感光体
DE3819051A1 (de) 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
JPH04503957A (ja) 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
JPH0369292A (ja) 1989-08-08 1991-03-25 Sharp Corp スロー再生における縦揺れ補正装置
ATE139255T1 (de) 1989-10-24 1996-06-15 Gilead Sciences Inc Oligonukleotidanaloga mit neuartigen bindungen
EP0527704B1 (de) 1991-08-08 1996-08-28 Ciba-Geigy Ag Farbstoffe, Verfahren zu deren Herstellung und deren Verwendung
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
EP0669323B2 (de) 1994-02-24 2004-04-07 Haarmann & Reimer Gmbh Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren
US6004719A (en) 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
US5596025A (en) 1994-06-30 1997-01-21 Minnesota Mining And Manufacturing Company Dental impression material with cure-indicating dye
EP0767809B1 (en) 1994-06-30 2004-01-21 Minnesota Mining And Manufacturing Company Cure-indicating molding and coating composition
JPH0815917A (ja) 1994-07-01 1996-01-19 Mitsubishi Chem Corp 静電荷像現像用帯電制御剤
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JPH08175992A (ja) 1994-12-21 1996-07-09 Sagami Chem Res Center 神経成長因子産生促進剤および縮環型オキサゾール化合物
JP3216458B2 (ja) 1994-12-28 2001-10-09 富士レビオ株式会社 アミド誘導体
US6222044B1 (en) 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5567843A (en) 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US5977101A (en) 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
JP3069292B2 (ja) 1996-06-13 2000-07-24 株式会社分子バイオホトニクス研究所 カテコール化合物及びバニリル化合物の蛍光検出用固相化試薬および検出方法
US5645948A (en) 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US6110638A (en) 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US5914213A (en) 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
FR2757389B1 (fr) 1996-12-24 1999-02-05 Oreal Composition cosmetique filtrante
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6177572B1 (en) 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
JPH11171881A (ja) 1997-09-30 1999-06-29 Mitsubishi Chemical Corp 含酸素複素環誘導体
WO1999016761A1 (fr) 1997-09-30 1999-04-08 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6312822B1 (en) 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
SE9804465D0 (sv) 1998-12-22 1998-12-22 Amersham Pharm Biotech Ab A method for the removal/purification of serum albumins and means for use in the method
FR2789581B1 (fr) 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789582B1 (fr) 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
AU4562000A (en) 1999-05-07 2000-11-21 Basf Aktiengesellschaft 4-(3',4'-heterocyclyl benzoyl) pyrazoles as herbicidal agents
CA2373137A1 (en) 1999-05-07 2000-11-16 Basf Aktiengesellschaft Benzohetero cyclylcyclo hexenones and their use as herbicides
FR2794645B1 (fr) 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
MXPA01013232A (es) 1999-07-20 2005-05-24 Pharmexa As Metodo para identificar la actividad de gdf-8.
JP2001039034A (ja) 1999-08-03 2001-02-13 Mitsui Chemicals Inc 光記録媒体
GB2353038A (en) 1999-08-12 2001-02-14 Eastman Chem Co Polyolefin composition comprising non-migrating optical brightener
KR20020032618A (ko) 1999-09-24 2002-05-03 우에노 도시오 히드록삼산 유도체 화합물, 그 제조 방법 및 그 화합물을유효 성분으로 하는 의약
NZ518420A (en) 1999-11-05 2004-02-27 Sod Conseils Rech Applic Heterocyclic compounds having an inhibitory activity on calpains or a trapping activity on reactive oxygen species (ROS's) and their use as medicines
US6565987B2 (en) 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
EP1593689A3 (en) 2000-01-18 2006-04-05 Ovita Limited Myostatin and mimetics thereof
GB0003256D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
JP2001261664A (ja) 2000-03-15 2001-09-26 Konica Corp ハロゲン化銀写真感光材料、画像形成方法並びに化合物及びその合成方法
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US6716413B1 (en) 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
FR2816509B1 (fr) 2000-11-15 2004-02-06 Sod Conseils Rech Applic Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene
EP1349851A4 (en) 2000-11-16 2004-09-08 Smithkline Beecham Corp COMPOUNDS
KR100846526B1 (ko) 2000-11-30 2008-07-15 캐논 가부시끼가이샤 발광 소자 및 표시 장치
FR2818142B1 (fr) 2000-12-18 2003-12-26 Oreal Compositions antisolaires a base d'un base melange synergetique de filtres et utilisations
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
DE10123711A1 (de) 2001-05-15 2003-02-27 Wolfgang Altmeyer Verfahren zur Bestimmung der Herkunft biologischer Materialien
JP2003005356A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
US6702667B2 (en) 2001-08-23 2004-03-09 Igt Apparatus for heating and/or cooling a beverage on a gaming apparatus
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
KR100438706B1 (ko) 2001-12-10 2004-07-05 삼성전자주식회사 전력 절감 기능을 갖는 전력 공급 장치 및 방법
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
JP4294917B2 (ja) 2002-07-02 2009-07-15 三井化学株式会社 光記録媒体およびオキサゾール化合物
WO2004035522A1 (ja) 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP1581217A4 (en) 2002-11-01 2007-07-11 Merck & Co Inc CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
WO2004069394A2 (en) 2003-02-03 2004-08-19 The Trustees Of Columbia University In The City Of New York Synthetic method for direct arylation of heterocyclic arenes
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US6992096B2 (en) 2003-04-11 2006-01-31 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007500219A (ja) 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
WO2005000295A1 (en) 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
DE602004021120D1 (de) 2003-09-22 2009-06-25 Agfa Graphics Nv Photopolymerisierbare zusammensetzung.
FR2863268B1 (fr) 2003-12-09 2006-02-24 Sod Conseils Rech Applic Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
US7097888B2 (en) 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
EP1720828A2 (en) 2004-02-06 2006-11-15 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
JP4695133B2 (ja) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
WO2005124563A2 (en) 2004-06-12 2005-12-29 Ceptor Corporation Compounds and kits for treating muscle disorders and methods of use thereof
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
CN101031294A (zh) 2004-07-29 2007-09-05 先灵-普劳有限公司 Alk5抑制剂在调节或抑制导致动物瘦肉组织添加生长增强的肌肉生长抑制素活性中的用途
US20070258912A1 (en) 2004-08-09 2007-11-08 Werner Holzl Use of Fluorescent Whitening Agents as Antimicrobials
CN101006159B (zh) 2004-08-19 2011-11-09 Lg化学株式会社 包括缓冲层的有机发光器件及其制备方法
WO2006044456A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
BRPI0406040B1 (pt) 2004-10-21 2018-09-11 Universidade Federal Do Rio De Janeiro - Ufrj compostos capazes de absorver radiação ultravioleta, composições contendo os mesmos e processos para sua preparação
WO2006051410A1 (en) 2004-11-15 2006-05-18 Pfizer Inc. Azabenzoxazoles for the treatment of cns disorders
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
AU2006218404A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
AU2006223070B2 (en) 2005-03-14 2012-02-09 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
PT1874306E (pt) 2005-04-08 2012-10-11 Ptc Therapeutics Inc Composições de um 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações sem sentido (ou nonsense)
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
ES2431050T3 (es) 2005-08-04 2013-11-22 Sirtris Pharmaceuticals, Inc. Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína
FR2889700B1 (fr) 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
JP2007086165A (ja) 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
WO2007045761A1 (fr) 2005-10-21 2007-04-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'amidine et leurs applications a titre de medicament
KR100890862B1 (ko) 2005-11-07 2009-03-27 주식회사 엘지화학 유기 발광 소자 및 이의 제조 방법
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
ES2455166T3 (es) 2005-12-02 2014-04-14 Sachem, Inc. Procedimiento de cromatografía de desplazamiento de intercambio aniónico
KR101213485B1 (ko) 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
DK1986633T3 (da) * 2006-02-10 2014-11-03 Summit Corp Plc Behandling af duchennes muskeldystrofi
WO2007096362A1 (en) 2006-02-21 2007-08-30 Trigen Limited Heterocyclic compounds and their use in the treatment of cardiovascular disease
JP4649645B2 (ja) 2006-03-10 2011-03-16 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
KR101325062B1 (ko) 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
US20070287344A1 (en) * 2006-06-12 2007-12-13 Hiroshi Ohara Fabric Construction Specifically For Damper
PT2170396T (pt) 2007-08-03 2017-03-31 Summit Corp Plc Combinação de fármacos para o tratamento da distrofia muscular de duchenne

Also Published As

Publication number Publication date
JP2010535708A (ja) 2010-11-25
HRP20170313T1 (hr) 2017-04-21
US20110195932A1 (en) 2011-08-11
PT2170396T (pt) 2017-03-31
PL2170396T3 (pl) 2017-07-31
AR068332A1 (es) 2009-11-11
EP2170396A1 (en) 2010-04-07
WO2009019504A1 (en) 2009-02-12
ES2617957T3 (es) 2017-06-20
PE20090510A1 (es) 2009-05-22
TW200911237A (en) 2009-03-16
RS55735B1 (sr) 2017-07-31
CA2685540C (en) 2018-10-16
BRPI0811317A2 (pt) 2015-01-27
EP3251694A1 (en) 2017-12-06
DK2170396T3 (en) 2017-03-13
EP2170396B1 (en) 2016-12-21
US20140011782A1 (en) 2014-01-09
CA2685540A1 (en) 2009-02-12
MX2009012558A (es) 2010-04-21
CL2008002279A1 (es) 2009-11-27
AU2008285289A1 (en) 2009-02-12
SI2170396T1 (sl) 2017-04-26
HUE033195T2 (en) 2017-11-28
US8501713B2 (en) 2013-08-06
CN101678107A (zh) 2010-03-24
CY1118700T1 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
PL2170396T3 (pl) Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of Duchenne muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
IL192299A0 (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
PL2500047T3 (pl) Uwalniające lek powłoki do urządzeń medycznych
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
ZA200806986B (en) Treatment of duchenne muscular dystrophy
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL200032A0 (en) Medicament for the treatment of endometriosis
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0715088D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
ZA200905300B (en) Medicament for the treatment of endometriosis
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0807216D0 (en) Drug combination for the treatment of duchenne muscular dystrophy
GB0602767D0 (en) Treatment of muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0619281D0 (en) Treatment of duchenne muscular dystrophy
GB0619283D0 (en) Treatment of duchenne muscular dystrophy
GB0617739D0 (en) Treatment of duchenne muscular dystrophy